| Literature DB >> 36014916 |
Yue Yang1,2, Genyuan Li2, Fang Li2, Fangping Xu2, Ping Hu2, Zhencheng Xie2, Xiaolong Lu2, Ye Ding2, Zhixu Wang2.
Abstract
Population research on the intervention of docosahexaenoic acid (DHA) supplementation in lactating women is in its infancy in China. This study investigated the effect of DHA supplementation on DHA concentrations in the breast milk of lactating women, and the intervention effect, with respect to different dietary patterns. In this trial, 160 healthy lactating women in Nanjing (30-50 days postpartum) were recruited and randomly divided into control (one placebo capsule of similar appearance per day) and supplement (one capsule with 200 mg of DHA from algal oil per day) groups for 8 weeks. Before and after the intervention, all subjects were asked to maintain basic information, maternal anthropometric parameters, breast milk (10-15 mL) sample collection, and a dietary survey using a food frequency questionnaire. The concentrations of DHA and other fatty acids in breast milk were detected using capillary gas chromatography. This study was completed by 137 subjects, with 60 in the control group and 77 in the supplement group. Compared with the DHA concentrations in the breast milk at enrollment, the absolute concentrations of the control group showed a significant decrease at the end of the trial (p = 0.037). In addition, after intervention, the absolute and relative DHA concentrations in the supplement group (10.07 mg/100 mL and 0.40%, respectively) were higher than those in the control group (7.57 mg/100 mL and 0.28%, respectively), being statistically significant (p = 0.012 and p = 0.001). Furthermore, the maternal diet in the supplement group was divided into four dietary patterns. Pattern 1 mainly included fruits and livestock meat. Pattern 2 was dominated by milk and its products, eggs, fish, shrimp and shellfish, and soybeans and its products. Pattern 3 chiefly comprised cereal and beans other than soybeans, potatoes, and nuts. Pattern 4 was high in poultry meat and low in cooking oils. The change in the absolute concentration of DHA in Pattern 3 was lower than that in other patterns (p < 0.05). In conclusion, DHA supplementation in lactating mothers increased breast milk DHA concentrations. The dietary pattern mainly characterized by cereal and beans other than soybeans, potatoes, and nuts may contribute to the poor intervention effect.Entities:
Keywords: DHA; breast milk; intervention; lactating women
Mesh:
Substances:
Year: 2022 PMID: 36014916 PMCID: PMC9415549 DOI: 10.3390/nu14163410
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Flow diagram for study subjects.
Demographic characteristics of the lactating women in this study.
| Characteristics | Control Group | Supplement Group | t/χ² | |
|---|---|---|---|---|
| Age, year (mean ± SD) | 29.8 ± 3.2 | 29.7 ± 4.0 | 0.193 | 0.847 |
| Education, | 1.333 | 0.721 | ||
| High school education or lower | 10 (16.7) | 11 (14.3) | ||
| Vocational–technical school education | 12 (20.0) | 18 (23.4) | ||
| University education or higher | 38 (63.3) | 48 (62.3) | ||
| Gestational age, week | 39.0 ± 1.0 | 39.0 ± 1.4 | −0.053 | 0.958 |
| Parity, | 0.136 | 0.712 | ||
| 1 | 40 (66.7) | 49 (63.6) | ||
| ≥2 | 20 (33.3) | 28 (36.4) | ||
| Height, cm | 160.5 ± 7.0 | 162.0 ± 5.0 | −0.864 | 0.388 |
| Pre-pregnancy weight, kg | 54.0 ± 9.8 | 55.0 ± 8.0 | −1.273 | 0.203 |
| Weight at delivery, kg | 69.5 ± 12.0 | 70.0 ± 9.0 | −1.390 | 0.164 |
| Pre-pregnancy BMI, kg/m2 | 21.1 ± 2.5 | 21.3 ± 3.8 | −0.822 | 0.411 |
| Pre-pregnancy BMI category a, | 1.605 | 0.658 | ||
| Underweight | 6 (10.0) | 10 (13.0) | ||
| Normal weight | 46 (76.7) | 54 (70.1) | ||
| Overweight | 7 (11.7) | 9 (11.7) | ||
| Obesity | 1 (1.7) | 4 (5.2) | ||
| Weight gain during pregnancy, kg | 15.0 ± 5.4 | 15.0 ± 5.5 | −0.687 | 0.492 |
| Weight at enrollment, kg | 60.0 ± 10.0 | 61.0 ± 8.75 | −1.521 | 0.128 |
| BMI at enrollment, kg/m2 | 23.3 ± 2.4 | 23.8 ± 2.8 | −1.15 | 0.252 |
| BMI category at enrollment | 1.899 | 0.387 | ||
| Underweight | 0 | 0 | ||
| Normal weight | 36 (60.0) | 43 (55.8) | ||
| Overweight | 23 (38.3) | 29 (37.7) | ||
| Obesity | 1 (1.7) | 5 (6.5) |
Data are expressed as median ± IQR, or number and percentage (n (%)) for categorical variables unless otherwise specified. p values were assessed using the Mann–Whitney U rank sum test for non-normally distributed continuous variables or the χ² test for categorical variables.
Maternal dietary intakes of energy and nutrients between the control and supplement groups at the time of enrollment and the end of the trial.
| Intakes | At Enrollment | At the End of the Trial | ||||
|---|---|---|---|---|---|---|
| Control Group | Supplement Group | Control Group | Supplement Group | |||
| Energy, kcal/d | 2335.41 ± 715.35 | 2294.49 ± 583.43 | 0.374 Δ | 2160.21 ± 824.95 | 2155.68 ± 579.99 | 0.484 Δ |
| Protein, g/d | 101.99 ± 35.56 | 96.18 ± 44.33 | 0.338 | 86.15 ± 41.01 | 87.48 ± 33.79 | 0.890 |
| Protein, %E | 17.23 ± 4.38 | 17.42 ± 4.84 | 0.632 Δ | 15.87 ± 3.53 | 16.71 ± 3.93 | 0.397 Δ |
| Fat, g/d | 89.11 ± 28.41 | 85.86 ± 26.69 | 0.314 | 78.66 ± 34.78 | 78.42 ± 21.77 | 0.549 |
| Fat, %E | 33.53 ± 8.86 | 33.75 ± 7.98 | 0.603 | 33.11 ± 10.08 | 33.09 ± 7.53 | 0.535 |
| Carbohydrates, g/d | 290.37 ± 110.80 | 282.82 ± 108.31 | 0.799 Δ | 273.86 ± 121.95 | 267.50 ± 112.06 | 0.652 |
| Carbohydrates, %E | 48.89 ± 11.50 | 49.52 ± 10.71 | 0.478 Δ | 50.90 ± 10.86 | 51.40 ± 9.88 | 0.709 Δ |
| Total fatty acids, g/d | 78.86 ± 19.96 | 74.49 ± 20.77 | 0.270 | 67.74 ± 30.97 | 68.71 ± 22.14 | 0.758 |
| SFA, g/d | 20.73 ± 7.07 | 20.76 ± 8.74 | 0.528 Δ | 17.25 ± 9.93 | 17.75 ± 8.74 | 0.972 |
| SFA, %E | 8.06 ± 3.08 | 8.03 ± 2.69 | 0.986 | 7.71 ± 3.00 | 7.83 ± 2.87 | 0.853 Δ |
| MUFA, g/d | 33.84 ± 12.19 | 32.39 ± 11.25 | 0.304 | 30.45 ± 14.37 | 30.62 ± 9.81 | 0.330 Δ |
| PUFA, g/d | 23.26 ± 6.95 | 22.02 ± 7.12 | 0.223 | 20.77 ± 7.95 | 20.87 ± 9.80 | 0.591 |
| PA, g/d | 11.59 ± 7.42 | 10.42 ± 7.22 | 0.265 | 9.43 ± 9.16 | 8.43 ± 7.54 | 0.549 |
| SA, g/d | 4.89 ± 3.14 | 4.37 ± 3.32 | 0.524 | 3.57 ± 3.62 | 3.70 ± 2.95 | 0.938 |
| POA, g/d | 1.25 ± 1.03 | 1.15 ± 1.08 | 0.410 | 0.91 ± 0.92 | 0.88 ± 0.86 | 0.818 |
| OA, g/d | 22.47 ± 14.01 | 18.64 ± 12.96 | 0.187 | 17.04 ± 19.48 | 15.76 ± 14.10 | 0.541 |
| LA, g/d | 17.61 ± 10.81 | 14.98 ± 9.60 | 0.072 | 13.24 ± 9.65 | 13.44 ± 9.83 | 0.448 |
| ALA, g/d | 2.43 ± 3.66 | 2.13 ± 1.37 | 0.087 | 2.05 ± 2.25 | 1.84 ± 1.48 | 0.371 |
| ARA, g/d | 0.23 ± 0.36 | 0.22 ± 0.26 | 0.410 | 0.17 ± 0.21 | 0.17 ± 0.23 | 0.835 |
| EPA, g/d | 36.19 ± 59.28 | 32.04 ± 72.04 | 0.371 | 17.93 ± 46.02 | 18.92 ± 59.34 | 0.619 |
| DHA, g/d | 48.92 ± 51.73 | 40.5 ± 50.69 | 0.211 | 31.95 ± 30.65 | 33.85 ± 43.37 | 0.607 |
| 2.57 ± 3.78 | 2.20 ± 1.37 | 0.077 | 2.14 ± 2.30 | 1.88 ± 1.59 | 0.367 | |
| 0.94 ± 1.07 | 0.85 ± 0.52 | 0.077 | 0.96 ± 0.87 | 0.88 ± 0.52 | 0.333 | |
| 17.74 ± 10.87 | 15.18 ± 9.83 | 0.072 | 13.56 ± 9.93 | 13.51 ± 10.00 | 0.415 | |
| 6.75 ± 3.46 | 6.26 ± 3.37 | 0.066 | 5.64 ± 4.83 | 5.68 ± 3.58 | 0.344 | |
| 6.66 ± 5.67 | 6.88 ± 5.00 | 0.349 | 6.45 ± 4.81 | 6.80 ± 5.19 | 0.872 | |
Δp values were assessed using independent samples t-test for normally distributed continuous variables. %E, the percentage of energy provided by the nutrient as a percentage of total energy. SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; PA, palmitic acid); SA, stearic acid; POA, palmitoleic acid; OA, oleic acid; LA, linoleic acid; ALA, α-linolenic acid; ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.
The absolute concentrations of fatty acids in breast milk between the control and supplement groups at the time of enrollment and the end of the trial.
| Fatty Acid, mg/100 mL | Control Group | Supplement Group | ||||||
|---|---|---|---|---|---|---|---|---|
| At Enrollment | At the End of the Trial | At Enrollment | At the End of the Trial | |||||
| Milk fat, g/100 mL | 3.86 ± 1.61 | 3.14 ± 2.03 | 3.70 ± 2.15 | 3.47 ± 2.30 | 0.483 | 0.716 | 0.128 | 0.688 |
| Total fatty acids | 3350.65 ± 1368.64 | 2766.48 ± 1581.62 | 3139.61 ± 1813.13 | 3018.65 ± 2039.50 | 0.306 | 0.712 | 0.122 | 0.895 |
| SFA | 1118.94 ± 396.45 | 962.79 ± 606.38 | 1039.70 ± 631.60 | 980.27 ± 617.43 | 0.140 | 0.661 | 0.116 | 0.810 |
| MUFA | 1212.41 ± 599.12 | 1100.84 ± 741.44 | 1243.36 ± 755.57 | 1134.22 ± 819.33 | 0.828 | 0.535 | 0.080 | 0.626 |
| PUFA | 884.47 ± 343.77 | 746.51 ± 503.29 | 813.39 ± 373.08 | 786.61 ± 520.33 | 0.288 | 0.938 | 0.327 | 0.920 |
| 807.80 ± 319.15 | 705.87 ± 463.12 | 733.88 ± 321.12 | 678.83 ± 474.72 | 0.241 | 0.805 | 0.430 | 0.895 | |
| 64.22 ± 44.33 | 60.48 ± 41.55 | 69.08 ± 48.19 | 69.73 ± 53.42 | 0.398 | 0.146 | 0.430 | 0.806 | |
| 11.92 ± 6.67 | 11.79 ± 8.04 | 10.72 ± 5.40 | 9.92 ± 6.01 | 0.136 | 0.005 | 0.534 | 0.059 | |
| LA | 731.60 ± 290.04 | 657.96 ± 400.72 | 664.96 ± 278.77 | 634.92 ± 445.66 | 0.247 | 0.768 | 0.467 | 0.937 |
| GLA | 6.16 ± 3.81 | 3.87 ± 2.91 | 5.10 ± 4.24 | 3.92 ± 2.80 | 0.243 | 0.811 | <0.001 | 0.093 |
| ALA | 46.71 ± 37.85 | 46.81 ± 42.16 | 50.32 ± 39.27 | 51.31 ± 47.02 | 0.443 | 0.233 | 0.697 | 0.788 |
| ARA | 21.68 ± 9.59 | 15.54 ± 9.97 | 21.54 ± 15.15 | 16.61 ± 12.74 | 0.771 | 0.671 | 0.001 | 0.031 |
| EPA | 1.33 ± 1.30 | 1.26 ± 1.30 | 1.46 ± 1.87 | 1.53 ± 2.05 | 0.828 | 0.335 | 0.928 | 0.244 |
| DHA | 10.55 ± 5.84 | 7.57 ± 6.30 | 11.88 ± 9.59 | 10.07 ± 13.16 | 0.531 | 0.012 | 0.037 | 0.873 |
| ARA/DHA | 2.01 ± 0.85 | 2.06 ± 1.30 | 2.00 ± 0.90 | 1.47 ± 1.06 | 0.742 | <0.001 | 0.328 | 0.003 |
SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; LA, linoleic acid; GLA, γ-linolenic acid; ALA, α-linolenic acid; ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid. a At enrollment: control group vs. supplement group; b At the end of the trial: control group vs. supplement group; c control group: at enrollment vs. at the end of the trial; d supplement group: At enrollment vs. At the end of the trial.
The relative concentrations of fatty acids in breast milk between the control and supplement groups at the time of enrollment and the end of the trial.
| Fatty Acid, % | Control Group | Supplement Group | ||||||
|---|---|---|---|---|---|---|---|---|
| At Enrollment | At the End of the Trial | At Enrollment | At the End of the Trial | |||||
| SFA | 34.99 ± 5.62 | 34.88 ± 4.52 | 33.85 ± 4.45 | 34.76 ± 5.56 | 0.063 Δ | 0.910 | 0.647 | 0.013 |
| MUFA | 38.25 ± 5.40 | 37.79 ± 6.77 | 39.58 ± 5.00 | 38.43 ± 5.15 | 0.072 Δ | 0.328 Δ | 0.630 | 0.062 |
| PUFA | 26.44 ± 6.82 | 26.84 ± 5.06 | 26.72 ± 5.37 | 25.74 ± 5.84 | 0.973 Δ | 0.124 Δ | 0.442 | 0.290 |
| 24.49 ± 6.36 | 24.67 ± 5.25 | 24.47 ± 5.22 | 23.08 ± 5.07 | 0.976 | 0.044 Δ | 0.558 | 0.142 | |
| 1.87 ± 0.93 | 2.12 ± 1.23 | 2.15 ± 0.98 | 2.41 ± 1.13 | 0.062 | 0.036 | 0.285 | 0.152 | |
| LA | 22.41 ± 6.00 | 23.30 ± 5.42 | 22.10 ± 4.84 | 21.16 ± 5.13 | 0.879 | 0.043 Δ | 0.285 | 0.476 |
| GLA | 0.18 ± 0.11 | 0.14 ± 0.08 | 0.16 ± 0.08 | 0.13 ± 0.07 | 0.286 Δ | 0.499 | <0.001 | <0.001 |
| ALA | 1.5 ± 0.78 | 1.63 ± 1.05 | 1.64 ± 0.75 | 1.83 ± 1.18 | 0.151 | 0.101 | 0.166 | 0.144 |
| ARA | 0.65 ± 0.23 | 0.56 ± 0.17 | 0.70 ± 0.23 | 0.59 ± 0.20 | 0.119 Δ | 0.642 | <0.001 | <0.001 |
| EPA | 0.04 ± 0.03 | 0.05 ± 0.04 | 0.04 ± 0.03 | 0.06 ± 0.04 | 0.706 | 0.422 | 0.316 | 0.284 |
| DHA | 0.32 ± 0.18 | 0.28 ± 0.15 | 0.34 ± 0.23 | 0.40 ± 0.29 | 0.248 | 0.001 | 0.277 | 0.858 |
Δ p values were assessed using independent samples t-test for normally distributed continuous variables. SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; LA, linoleic acid; GLA, γ-linolenic acid; ALA, α-linolenic acid; ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid. a At enrollment: control group vs. supplement group; b at the end of the trial: control group vs. supplement group; c control group: at enrollment vs. at the end of the trial; d supplement group: at enrollment vs. at the end of the trial.
Figure 2Comparison of the absolute(a) and relative (b) DHA concentrations in breast milk between the control and supplement groups before and after the intervention. ns: p > 0.05, * p < 0.05, *** p < 0.001.
Changes in DHA concentrations of breast milk with respect to dietary patterns in the supplement group.
| DHA | Pattern 1 ( | Pattern 2 ( | Pattern 3 ( | Pattern 4 ( | |
|---|---|---|---|---|---|
| Absolute concentration, mg/100 mL | −0.23 ± 8.22 | 1.52 ± 12.25 | −5.61 ± 10.91 | 2.29 ± 11.46 | 0.013 |
| Relative concentration, % | 0.05 ± 0.20 | 0 ± 0.39 | −0.08 ± 0.24 | 0.07 ± 0.20 | 0.267 Δ |
Δ p values were assessed using the analysis of variance for normally distributed continuous variables. p values were assessed using the Kruskal–Wallis test for non-normally distributed continuous variables.
Figure 3Changes in the absolute DHA concentrations of the breast milk with respect to dietary patterns in the supplement group. * p < 0.05, ** p < 0.01.